Monthly Archives: July 2018

SHAREHOLDER ALERT – Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Akers Biosciences, Inc. (AKER) & Lead Plaintiff Deadline: August 13, 2018

NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Akers Biosciences, Inc. (“Akers” or the “Company”) (NASDAQ: AKER) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Akers securities between May 15, 2017 through June 5, 2018, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/aker.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Akers was improperly recognizing revenue for the fiscal year ended December 31, 2017; (2) Akers had downplayed weaknesses in its internal controls over financial reporting and failed to disclose the true extent of those weaknesses; and (3) consequently, defendants’ statements about Akers’ business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On May 21, 2018, Akers revealed that it would delay filing its Form 10-Q with the SEC for the quarter ended March 31, 2018 and that will continue reviewing the “characterization of certain revenue recognition items . . . now includes certain transactions in previous quarters.” Following this news, Akers stock dropped $0.058 per share or over 8% to close at $0.599 per share on May 22, 2018.

On May 29, 2018, Akers announced that “Raymond F. Akers Jr., Ph.D. has resigned as a director of the Company with immediate effect.” Following this news, Akers stock dropped $0.198 per share or over 33% to close at $0.391 on May 29, 2018.

Then on June 1, 2018, Akers filed a letter with the SEC from Raymond Akers that said that Dr. Akers “resigned from the Board of Directors due to significant differences regarding the policies and practices of the Board of Directors, accounting and business practices of Management, and new Counsel.”

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/aker or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Akersyou have until August 13, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 507117

SHAREHOLDER ALERT – Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against PG&E Corporation (PCG) & Lead Plaintiff Deadline – August 13, 2018

NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against PG&E Corporation (“PG&E” or the “Company”) (NYSE: PCG) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired PG&E securities between April 29, 2015, and June 8, 2018, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/pcg.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) PG&E had failed to maintain electricity transmission and distribution networks in compliance with safety requirements and regulations promulgated under state law; (2) as a result, the Company was in violation of state law regulation; (3) PG&E’s electricity networks would cause numerous wildfires in California; and (4) consequently, Defendants’ statements about PG&E’s business and operations were materially false and misleading at all relevant times.

On June 9, 2018, Bloomberg published an article entitled “PG&E May Face Criminal Charges After Probe of Deadly Wildfires.” The article reported, in part, that following an investigation into the causes of wildfires “that altogether killed 44 people, consumed thousands of homes and racked up an estimated $10 billion in damages” in October 2017, California’s fire agency “found evidence of alleged violations of law by PG&E in connection with” the fires. Specifically, the state’s investigation found “that PG&E equipment caused at least 12 of the wine country blazes.” Following this news, PG&E’s share price fell $1.69, or 4.08%, to close at $39.76 on June 11, 2018, the following trading day.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/pcg or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in PG&Eyou have until August 13, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 507116

INVESTOR ALERT – Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $100K of Class Action Against Ormat Technologies, Inc. (ORA) & Lead Plaintiff Deadline: August 10, 2018

NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Ormat Technologies, Inc. (“Ormat” or the “Company”) (NYSE: ORA) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Ormat securities between August 8, 2017 and May 15, 2018, both dates inclusive (the “Class Period”).Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/ora.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) there were errors in the income tax provision primarily relating to Ormat’s valuation allowance based on its ability to utilize foreign tax credits in the U.S. prior to their expiration; (2) Ormat netted certain deferred income tax assets and deferred income tax liabilities across different tax jurisdictions that are not permitted to be netted pursuant to United States generally accepted accounting principles; (3) Ormat’s internal controls over financial reporting were ineffective; (4) Ormat would need to restate its second, third and fourth quarter 2017 financial statements and its full-year 2017 financial statements; and (5) as a result, defendants’ statements about Ormat’s business, operations and prospects were materially false and misleading and/or lacked a reasonable bases at all relevant times.

On May 11, 2018, Ormat disclosed that the Company was delaying the filing of its Quarterly Report for the period ended March 31, 2018 with the U.S. Securities and Exchange Commission, stating that “management has identified an error in the Company’s financial statement presentation of deferred income tax assets and deferred income tax liabilities that affects the Company’s balance sheets in previous reporting periods.” Ormat further disclosed that “[t]he Company is evaluating the impact of this error on its consolidated financial statements and the extent to which the Company’s annual and quarterly consolidated financial statements filed in previous periods require revision or amendment.” On this news, Ormat’s share price fell $3.58, or over 6%, over two consecutive trading days to close at $52.77 on May 14, 2018.

Then, on May 16, 2018, Ormat announced that the Company “will restate its second, third and fourth quarter 2017 financial statements and its full-year 2017 financial statements,” and stated that “investors should no longer rely upon the Company’s previously issued financial statements for [these] periods . . . , earnings releases for these periods, and other communications relating to these financial statements.” On this news, Ormat’s share price fell $0.67, or 1.26%, to close at $52.35 on May 16, 2018.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/ora or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Ormatyou have until August 10, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 507115

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Switch, Inc. (SWCH) & Lead Plaintiff Deadline: August 10, 2018

NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Switch, Inc. (“Switch” or the “Company”) (NYSE: SWCH) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Switch Class A common stock pursuant to and/or traceable to Switch’s Initial Public Offering (“IPO”) commenced on or around October 6, 2017. Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/swch.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1933.

The Complaint alleges that Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Switch’s Grand Rapids and Atlanta facilities would never be as profitable as its Las Vegas facility, diminishing the yield on Switch’s recent capital expenditures acquiring and building out those facilities will bear; (2) Switch’s high capital expenditures to create high redundancy levels at its facilities were not as profitable as they once had been in the past; (3) Switch had already spent an additional more than $64 million on unbudgeted capital expenditures during the third quarter of 2017 that was not disclosed to investors until after the IPO; (4) Switch recognized $9.4 million in revenues during FY17 that it would not provide colocation services for until FY18, meaning its reported FY17 revenue growth and its FY18 revenue prospects were both overstated; (5) eBay, Switch’s largest colocation customer, would not be taking possession of colocation space it had reserved at Switch’s Tahoe/Reno facility in early 2018; and (6) as a result of the foregoing, at the time of the IPO, Switch’s business and financial prospects were not what defendants had led the market to believe they were in the Registration Statement.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/swch or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Switch you have until August 10, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 507114

INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses in Excess of $100K of Class Action Against Deutsche Bank Aktiengesellschaft (DB) and Lead Plaintiff Deadline: August 6, 2018

NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Deutsche Bank Aktiengesellschaft (”Deutsche Bank” or the ”Company”) (NYSE: DB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Deutsche Bank securities between March 20, 2017 through May 30, 2018, inclusive (the ”Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/db.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Deutsche Bank’s internal control environment and infrastructure were materially weak and deficient; and (2) as a result, Deutsche Bank’s statements about the Company’s business and operations were materially false and misleading at all relevant times.

On May 31, 2018, the Wall Street Journal reported that the U.S. Federal Reserve has designated Deutsche Bank’s U.S. business to be in ”troubled condition,” citing concerns ”about its controls around measuring financial exposure to clients and valuing collateral that backed loans.” The article further reported that the Federal Deposit Insurance Corporation has added Deutsche Bank’s subsidiary Deutsche Bank Trust Company Americas to it’s ”problem banks” list of at-risk institutions. Following this news, Deutsche Bank’s share price fell $0.49, or 4.24%, to close at $11.08 on May 31, 2018.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/db or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Deutsche Bank you have until August 6, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 506641

INVESTOR ALERT: Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Lawsuit Filed Against National Beverage Corp. – FIZZ

RADNOR, PA / ACCESSWIRE / July 31, 2018 / The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors that a securities fraud class action lawsuit has been filed against National Beverage Corp. (NASDAQ: FIZZ) (“National Beverage”) on behalf of purchasers of National Beverage securities between July 17, 2014 and July 3, 2018, inclusive (the “Class Period”).

Investors who purchased National Beverage securities during the Class Period may, no later than September 17, 2018, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this action please visit https://www.ktmc.com/new-cases/national-beverage-corp-2018#join..

The complaint was filed on July 17, 2018, in the United States District Court for the Southern District of Florida.

The complaint alleges that during the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that: (i) National Beverage’s sales claims and the supposed underlying “proprietary techniques” lacked a verifiable basis; (ii) National Beverage’s Chairman and Chief Executive Officer, Nick A. Caporella, engaged in a pattern of sexual misconduct between 2014 and 2016; and (iii) as a result, National Beverage’s public statements were materially false and misleading at all relevant times.

National Beverage investors who wish to discuss this securities fraud class action and their legal options are encouraged to contact Kessler Topaz Meltzer & Check, LLP (James Maro, Jr., Esq. or Adrienne Bell, Esq.) at (888) 299-7706 or at info@ktmc.com.

National Beverage investors may, no later than September 17, 2018, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check. For more information about Kessler Topaz Meltzer & Check, please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
(888) 299-7706
(610) 667-7706
info@ktmc.com

SOURCE: Kessler Topaz Meltzer & Check, LLP

ReleaseID: 507511

Newgioco Group Announces Proven Expertise with New Independent Board Members

NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Newgioco Group, Inc. (OTCQB: NWGI) (”Newgioco” or the ”Company”) a leisure betting technology company providing regulated sports betting and gaming products and services, is pleased to announce the appointment of Russ McMeekin, Harold Wolkin and William (Bill) Rutsey to the Company’s board of directors. The change, which took effect on July 23, 2018, represents the next phase of Newgioco’s corporate evolution and strengthening of the Company’s non-executive board of directors in preparation for entering the rapidly developing USA regulated sports wagering market.

Russ McMeekin has over 25 years of professional experience in gaming, technology and executive management. Mr. McMeekin served as President, Chief Executive Officer and a member of the Board of Progressive Gaming International, an integrated gaming management systems provider who pioneered the use of embedded radio-frequency identification, also known as RFID, in poker chips and advanced sports betting systems included mobile gaming for the casino gaming industry worldwide. He also served as a member of the board of the American Gaming Association and the Canadian Gaming Association working on specific assignments related to sports and on-line wagering. In addition, Mr. McMeekin also currently serves as the Chief Executive Officer, President and co-founder of TSXV listed Universal mCloud, a Cloud and AI company with many similar technology attributes as Newgioco. He previously served as the Chief Executive Officer of SCI Energy, Executive Chairman of Yokogawa Venture Group and held a variety of senior executive capacities at Honeywell International including Global President of Advanced Software and Internet Business.

Harold M. Wolkin, is an executive, investment banker and financial analyst with over 30 years of proven business success. Mr. Wolkin previously served as Executive Vice President, and Head of Investment Banking of Dundee Capital Markets; Co-Founder, Vice Chairman, Head of Investment Banking of Sandfire Securities, Inc; Managing Director, Diversified Industries; Investment and Corporate Banking; Vice President and Director, Equity Research Analyst of BMO Capital Markets and BMO Financial Group. In addition, Mr. Wolkin has held a variety of roles with Canada Trust Corporation, Royal Trust Corporation and Crown Life Insurance Company as well as serving on numerous boards and committees of exchange listed, private and non-for-profit companies including serving as vice chairman of the board and chair of the audit committee of TSX listed Baylin Technologies and Cipher Pharmaceuticals; and chairman of the governance and compensation committee of Diamond Estates Wine & Spirits. Mr. Wolkin is a Chartered Financial Analyst (”CFA”).

William (Bill) Rutsey, has had a highly accomplished career as a senior executive and an advisor to the public and private sectors in the gaming, sports and entertainment and real estate fields, culminating in his positions as Chief Executive Officer in the gaming industry in Nevada, Ontario and nationally in Canada. Mr. Rutsey founded the Canadian Gaming Association (the ”CGA”) in 2005 and served as its Chief Executive Officer until June 2017, where he was a national advocate for the gaming entertainment industry, responsible for positioning the association to address regulatory, political and educational issues in the industry, including being a regular commentator on gaming issues in media and before the government. Since June 2017 he has acted as an advisor to the CGA. Mr. Rutsey co-founded and served as Chairman of Canada’s pre-eminent annual gaming industry convocation, the Canadian Gaming Summit and also served as co-publisher of Canada’s premier gaming industry magazine, Canadian Gaming Business. Prior, in his role as Chief Executive Officer of RPC Gaming Inc. and Chief Executive Officer of Multigames International Inc, Mr. Rutsey developed and managed gaming businesses in Ontario, Las Vegas and internationally, including a chain of sports bars in Las Vegas, and has been licensed by gaming regulators in Nevada and Ontario. As founder and practice leader of the Coopers and Lybrand (now PricewaterhouseCoopers) Gaming Consulting Practice, he advised numerous private and public-sector clients, including the Ontario government, authoring the Ontario Casino Market and Economic Impact Study – the blueprint for the Ontario casino gaming industry. He also previously advised professional sports organizations on the design and development of new stadium and arena facilities and various levels of government on public infrastructure projects. In 2017, Mr. Rutsey received the Canadian Gaming Industry Leadership and Outstanding Contribution Award, which is awarded for lifetime achievement.

The new independent board members were contemporaneously appointed to board committee positions as follows:

Russ McMeekin will serve as Chair of the Compensation Committee; member of the Audit Committee and member of the Nomination and Corporate Governance Committee.

Harold Wolkin will serve as Chair of the Audit Committee, member of the Compensation Committee; and member of the Nomination and Corporate Governance Committee.

Bill Rutsey will serve as Chair of the Nomination and Corporate governance committee, member of the Compensation Committee; and member of the Audit Committee.

Each of our new directors bring wealth of global experience across a variety of different industry groups along with extensive experience in gaming operations and strategy with significant scale to form Newgioco into a world-class sport betting and gaming technology company. Working in harmony with the new board, Company management expects to start the process of preparing itself for expansion outside of its core market in Italy and into strategically defined regulated jurisdictions around the world. The teams’ strategy on the US market will prove to be a highly valuable asset as we pursue opportunity in the US for significant expansion in the regulated sports betting market and online gaming and brings a fresh perspective to our current activities in other markets. Newgioco expects to be an innovative leader in these new jurisdictions leveraging it’s solid foundation and deep experience in Cloud and AI technologies. Newgioco will build from its highly differentiated technology position in Italy and will leverage its new board to expand this as well as its Capital markets reach.

”I am absolutely thrilled to have Russ, Harold and Bill enthusiastically embrace the opportunity to have significant roles in building the early foundations of Newgioco Group. Indeed the transformation deepens not only our corporate bench and also our business playbook as we set out to become a world leader in leisure betting for years to come. We believe that the extraordinary qualifications of the new governing team is major transformation for Newgioco which is now positioned to enter the rapidly developing U.S. sports wagering market on the back of the recent U.S. Supreme Court Ruling,” remarked company Chairman and CEO, Michele Ciavarella. ”Russ, Harold and Bill collectively bring more than 50 years of experience in the gaming industry and extensive talent in areas such as corporate governance, mergers and acquisitions, initial public offerings, joint ventures, corporate governance, financial reporting, long term budgetary oversight as well as both financial and business strategy. The strong independent board coupled with a highly talented and respected executive team are key ingredients to make our U.S. deployment plan a huge success and with our plans to list on the NASDAQ stock market.”

About Newgioco Group, Inc.

Newgioco Group, Inc., together with its subsidiaries, is a fully integrated, licensed gaming technology company. The Company conducts its business primarily through retail neighborhood betting shops and internet-based betting software platform under the registered brand Newgioco through our licensed website www.newgioco.it situated in Italy.

The Company offers its clients a full suite of leisure gaming products and services, such as sports betting, virtual sports, online casino, poker, bingo, lottery, interactive games and slots, as well as an innovative betting platform (www.odissea.at) providing both B2B and B2C bet processing. Additional information is available on our corporate website at www.newgiocogroup.com.

Investors may also find us on Facebook® and follow us on Twitter @NWGI_gaming.

Cautionary Statement Regarding Forward Looking Statements

Except for the historical information contained herein, this press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as “anticipates,” “believes,” “estimates,” “expects,” “forecast,” “plans,” “intends,” “potential” and similar expressions. These statements reflect the Company’s current beliefs and are based upon currently available information. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance or achievements to differ materially from those expressed in or implied by such statements, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the fiscal year ended December 31, 2017, as amended by the Company’s Quarterly Report on Form 10-Q. One or more of these factors have affected, and in the future, could affect our businesses and financial results in the future and could cause actual results to differ materially from plans and projections. Therefore, because of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. All forward-looking statements made in this release are based on information presently available to our management. We assume no obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Investor Relations Contact

Newgioco Group, Inc.
investor@newgiocogroup.com

SOURCE: Newgioco Group, Inc.

ReleaseID: 507508

CORRECTION: Cannabis and Biotech Firms Set to Explode

HENDERSON, NV / ACCESSWIRE / July 31, 2018 / Biotech and Cannabis companies are starting to heat up once again. We have identified two companies that could greatly benefit from the action!

Everyone should start researching this undiscovered company right away, BRTX (BioRestorative Therapies, Inc.). BRTX is on the cusp of receiving major attention from the street. As BRTX prepares for it’s Phase 2 clinical trial using BRTX-100 to treat chronic lumbar disc disease, the company is flying under the radar currently, but that could all change in the blink of an eye. BRTX presents an incredible opportunity to investors that will have discovered the company before BRTX starts it’s phase 2 clinical trial using BRTX-100. The company just made an addition to their scientific advisory board, and more positive news could be on the way!

These two companies could benefit from increased attention in their respective sectors and industry: BioRestorative Therapies, Inc. (BRTX), and CV Sciences, Inc. (OTCQB: CVSI)

BioRestorative Therapies, Inc. (BRTX)

Market Cap: $10.57M Share Price: $1.59

BioRestorative Therapies, Inc. (BRTX), a life sciences company focused on stem cell-based therapies, recently announced the appointment of Jason S. Lipetz, M.D. to the Company’s Scientific Advisory Board. Dr. Lipetz has an impressive resume and will certainly add clinical expertise as the Company prepares for its Phase 2 trial using BRTX-100 to treat chronic lumbar disc disease. So far the stock has been trading sideways, announcements like these many times lead to more news in the near future. Investors should monitor this situation closely.

CV Sciences, Inc. (OTCQB: CVSI)

Market Cap: $262.0M Share Price: $2.89

CV Sciences, Inc. is a supplier and manufacturer of hemp-based phytocannabinoids including cannabidiol (CBD) oil and developer of specialty pharmaceutical therapeutics. The Company recently had news showing unaudited second quarter 2018 revenue. Second quarter 2018 revenue is expected to be USD 12.3 Million, up over 200% to the second quarter of 2017.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and seven thousand dollars total by Regal Consulting. LLC, for news commentary articles for BRTX. BRTX and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. ACR Communication, LLC, will not buy or sell any shares in stocks contained within this article for forty eight hours after this article’s distribution.

For Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators
Contact Person: Media Manager
Email: info@microcapspecualtors.com
Phone: 1-702-720-6310
Country: United States
Website: http://microcapspeculators.com/

SOURCE: ACR Communication, LLC

ReleaseID: 507509

Nonallergic Rhinitis Market Is Expected To Generate Huge Profits: Top Vendors | Treatment | Diagnosis and CAGR of 5.3 % during forecast period 2017 to 2023

Market Research Future with their unique quality of simplifying the market research study, announces a deep study report on “Nonallergic Rhinitis Market Research Report – Global Forecast till 2023” Gives industry size, top players and worldwide demand

Pune, India – July 31, 2018 /MarketersMedia/

Market Synopsis of the Global Nonallergic Rhinitis Market
Also known as vasomotor rhinitis, nonallergic rhinitis is a medical condition that causes chronic sneezing, and congestion. Although the symptoms of nonallergic rhinitis are similar to that of allergic rhinitis, it does not involve the immune system. This condition can be diagnosed with, physical examination, allergy test such as skin test, blood test, and imaging tests such as CT scan. Treatment includes use of nasal sprays, oral decongestants, and over-the-counter (OTC) drugs or prescription medications.
Rising prevalence of nonallergic rhinitis, and increasing demand for diagnosis and treatment of nonallergic rhinitis are the major factors driving the growth of the market across the globe. Furthermore, increasing healthcare expenditure and overall growth of healthcare industry also influences the market growth. Splendid research in the field of immunology also boost the market. Additionally, increasing focus on the development of new medications for the treatment of nonallergic rhinitis, and increasing use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) also fuel the market growth. The growth of the market is restricted by increasing competition among key players in the market that act as a barrier of new entrants.
The global nonallergic rhinitis market is expected to grow at a CAGR of 5.3% during the forecast period.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/5137

Segments

The global nonallergic rhinitis market is segmented on the basis of diagnosis, treatment, and end user.
On the basis of diagnosis, market is categorized into physical examination, allergy testing, imaging test, and other segments. Allergy testing is further segmented into skin test and blood test. Imaging test is further segmented into nasal endoscopy, and computerized tomography (CT) Scan.
On the basis of treatment, the market is segmented into nasal sprays, NSAIDs and others.
Nasal sprays is further segmented into saline, corticosteroid, antihistamine, decongestants, and anti-drip anticholinergic.
On the basis of end user, the market is segmented into hospitals & clinics, research centers, and others.

Intended Audience
• Medical Device Manufacturers
• Medical Device Suppliers
• Medical Research Laboratories
• Healthcare IT Companies
• Research and Development (R&D) Companies
• Market Research and Consulting Service Providers
• Potential Investors

Regional Analysis of the Global Nonallergic Rhinitis Market

America holds the first position in the market for nonallergic rhinitis owing to the rising prevalence of nonallergic rhinitis in the U.S., and consequent increase in the demand for new diagnostic and treatment services. In Americas, North America is the largest market owing to the presence of key players in the industry. As per the Warren Alpert Medical School of Brown University, the prevalence of nonallergic rhinitis has been observed to be one-third that of allergic rhinitis, affecting ~7% of the U.S. population or ~22 million people. Additionally, rising awareness about morbidity due to nonallergic rhinitis and the presence of key players in the market also influence the growth of the market.
Europe is the second largest market for nonallergic rhinitis. In Europe, there is an increasing demand for nasal sprays, and extensive research and development activities by clinical research and academic institutes for chronic diseases treatment. Germany, and France are the largest contributors to the market growth owing to an increase in the number of market players manufacturing NSAIDs, and overall growth of healthcare industry.
The market in Asia Pacific is expected to grow at the fastest pace and is driven by an increasing number of patients suffering from nonallergic rhinitis and increasing awareness about the diagnosis and treatment. India, China, and Japan are major contributors to the growth of the market. This growth is attributed to an increasing demand for nasal sprays and OTC medicines and availability of highly qualified medical personnel dedicated to the research of chronic diseases.
The Middle East & Africa also show a steady rise in the market owing to low prevalence of nonallergic rhinitis and increasing awareness about allergic and nonallergic rhinitis treatment. In the Middle East & Africa, the Middle East captures the largest market share for availability of specialty medical services and increasing expenditure on healthcare

Key Players in the Global Nonallergic Rhinitis Market

Some of the key players in this market are Boehringer Ingelheim GmbH (Germany), Novartis (U.S.), GlaxoSmithKline (U.K), Perrigo Company plc (Ireland), Johnson & Johnson Consumer Inc. (U.S.), Bayer (U.S.), Sanofi (France) and others.

Apply for Exclusive Discount @ https://www.marketresearchfuture.com/check-discount/5137

Detailed Table of Contents:
Table Of Contents
1. Report Prologue
2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
11 Appendix

Send An Enquiry @ https://www.marketresearchfuture.com/enquiry/5137

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Info:
Name: Market Research Future
Email: sales@marketresearchfuture.com
Organization: Market Research Future
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune – 411028 Maharashtra, India
Phone: +1 646 845 9312

Source URL: https://marketersmedia.com/nonallergic-rhinitis-market-is-expected-to-generate-huge-profits-top-vendors-treatment-diagnosis-and-cagr-of-5-3-during-forecast-period-2017-to-2023/387188

For more information, please visit https://www.marketresearchfuture.com

Source: MarketersMedia

Release ID: 387188

Air Water Life Introduces New Antioxidant Enriched Alkaline Water Ionizer

Released under their parent company Real Spirit U.S.A., Air Water Life improves water quality, specifically via pH and alkaline measures, with advanced water purification systems.

Reno, United Kingdom – July 31, 2018 /NewsNetwork/

Reno, NV—In July of 2005, business partners and friends Richard Mayer and Dr. Malcolm Currie founded the parent company Real Spirit U.S.A. with an aim to develop products that were affordable and cutting edge.

This, their first company, has become an umbrella for numerous brand name lines, including Air Water Life, which has released some of the most advanced products in the lineup of water ionization systems. Now, they are announcing the newest addition to their product line—an alkaline ionizer that is antioxidant enriched.

With the numerous contaminants present in water, especially as production processes continue to increase and cause pollution of the available water supply, water purification systems are becoming increasingly necessary. Not only that, but much of the water, especially after undergoing decontamination, is not optimized for the best pH or alkaline levels that a body craves.

Many bottled water options at the store boast specific alkaline levels, and a specific pH. However, the tap water in most people’s homes does not provide these minerals and vitamins. Air Water Life is seeking to change this situation and allow more people to avail of advanced water purification systems with the introduction of their new antioxidant enriching alkaline water ionizer.

Most people will settle for the water out of the tap in their homes, but would nearly always prefer to use the filtration system built into the refrigerator, or some sort of filter to improve their water quality. Air Water Life strives to better the quality of water at home for all with their newest release, the Aqua Ionizer Deluxe 9.0. It is their most powerful and advanced water ionizer and is the seventh product released in this line.

Naturally dependent on the sourced water, this new ionizer can produce water with a pH measuring between 3.5 to 11.5. It also helps to boost the water’s antioxidant potential, and each of the inner activated carbon filters can clean and treat up to 4,000 liters.

Air Water Life has earned a reputation of engineering and distributing these innovative water products. They truly strive to provide healthy, accessible water for all consumer homes and design a number of accessories and systems for every budget and water need.

They are celebrating the release of this newest ionizer and are being recognized for their dedication to creating and providing continuously advanced yet affordable water purification and filtration systems for the home.

Contact Info:
Name: Robert Rowen
Email: Robert@realspiritusa.com
Organization: Air Water Life
Address: 320 S. Rock Blvd. St. 210, Reno, Nevada 89502, United Kingdom
Phone: +1-888-601-5886

For more information, please visit https://airwaterlife.com/

Source: NewsNetwork

Release ID: 385837